Change and prognostic significance of cardio-renal parameters in cardiosurgical interventions

niversitätsmedizin Göttingen0 个研究点目标入组 120 人开始时间: 2022年4月12日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Patients in whom the indication for one of the cardiosurgical therapies was made due to a symptomatic heart disease in the indications mentioned under groups 1-5:
•- Age >= 18 years
•- Patients able to consent and cooperate
•- Written consent to study participation
•Patients with high-grade aortic valve stenosis who receive surgical aortic valve replacement
•Patients with severe mitral valve regurgitation who receive surgical mitral valve reconstruction/replacement
•Patients with severe tricuspid regurgitation who receive surgical tricuspid valve reconstruction/replacement
•Patients with CHD who receive ACVB surgery and do not have defects > grade 2
•4A) with ejection fraction =50% (control group)
•4B) with ejection fraction <40%
•Patients receiving LVAD implantation
•In this group, due to the limited use of the method, it is unlikely that a high number of cases will be reached, so this group will be recruited in an exploratory approach until the other groups have been completed. A maximum number of N=20 is provided.

•Patients after a kidney transplant or requiring dialysis
•- Chronic renal failure CKD stage > G5 (<15 ml/min according to CKD EPI formula)
•- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
•- History of intrarenal disease (e.g. glomerulonephritis, interstitial nephritis)
•- Current acute kidney injury
•- Postrenal obstruction
•- Need for therapy with catecholamines or inotropics at inclusion in the study
•- Patients after heart transplantation
•- Established precapillary pulmonary hypertension
•- Circumstances that could interfere with the results of the Doppler sonographic evaluation or the biomarkers (e.g. significantly restrictive respiratory diseases, strongly fluctuating blood pressure values, etc.)
•- Pregnancy or lactation
•A board of two nephrologists assessed the exclusion criteria - the presence of acute renal failure and the severity of CKD.
•Group 4A (control group)

发起方

niversitätsmedizin Göttingen